Xencor (NASDAQ:XNCR) SVP Sells $17,754.80 in Stock

March 5, 2026 by InsiderTrades.com

Key Points

CEO Bassil Dahiyat sold 6,758 shares on March 3 at an average price of $11.90 for total proceeds of $80,420, reducing his stake by 1.18% to 567,792 shares (valued at about $6.76M); the trade was disclosed in an SEC filing.
Xencor shares and results: the stock traded down to $11.22 on heavy volume, the company reported Q results with EPS of ($0.09) (beating the ($0.64) estimate) and revenue of $28.24M (down 46.6% YoY and slightly below estimates); market cap is roughly $823M and analysts’ consensus is a “Moderate Buy” with a $25 price target amid mixed ratings.

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) SVP Celia Eckert sold 1,492 shares of the firm's stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $11.90, for a total transaction of $17,754.80. Following the transaction, the senior vice president directly owned 81,929 shares of the company's stock, valued at approximately $974,955.10. This trade represents a 1.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Xencor Price Performance

Xencor stock traded down $1.50 during mid-day trading on Thursday, hitting $11.24. 865,363 shares of the company were exchanged, compared to its average volume of 685,250. Xencor, Inc. has a 12-month low of $6.92 and a 12-month high of $18.69. The company has a market capitalization of $824.33 million, a P/E ratio of -9.06 and a beta of 0.95. The business's 50 day simple moving average is $12.96 and its two-hundred day simple moving average is $12.91. The company has a debt-to-equity ratio of 0.12, a current ratio of 6.25 and a quick ratio of 6.25.

Xencor (NASDAQ:XNCR - Get Free Report) last announced its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.64) by $0.55. Xencor had a negative net margin of 73.20% and a negative return on equity of 14.58%. The firm had revenue of $28.24 million during the quarter, compared to the consensus estimate of $29.97 million. During the same quarter in the previous year, the company posted ($0.62) EPS. The firm's revenue for the quarter was down 46.6% on a year-over-year basis. Analysts forecast that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on XNCR. Wedbush restated an "outperform" rating and set a $26.00 price objective on shares of Xencor in a report on Thursday, November 6th. Weiss Ratings restated a "sell (d-)" rating on shares of Xencor in a report on Monday, December 29th. JPMorgan Chase & Co. decreased their price target on shares of Xencor from $20.00 to $18.00 and set an "overweight" rating on the stock in a report on Thursday, November 6th. Cantor Fitzgerald upped their price objective on Xencor from $40.00 to $42.00 and gave the stock an "overweight" rating in a report on Thursday, November 6th. Finally, Barclays lifted their target price on Xencor from $26.00 to $27.00 and gave the company an "overweight" rating in a report on Thursday, February 26th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Xencor has an average rating of "Moderate Buy" and a consensus target price of $25.00.

Check Out Our Latest Stock Analysis on XNCR

Trending Headlines about Xencor

Here are the key news stories impacting Xencor this week:

Positive Sentiment: Recent quarterly results showed an EPS beat (reported 2/25), and Xencor’s balance sheet remains strong (high quick/current ratios), which limits near‑term financing risk and supports long‑term program funding. MarketBeat: Xencor company page
Neutral Sentiment: CEO Bassil Dahiyat disclosed a sale of 6,758 shares at an average of $11.90 (≈$80k); the sale reduced his ownership by ~1.18% — notable but relatively small as a percentage of his holdings and possibly routine diversification. InsiderTrades: CEO share sale
Negative Sentiment: Reported royalty dispute: Alexion (operator of Ultomiris) has cut off U.S. royalty payments to Xencor, and Xencor announced it is revising its Ultomiris royalty revenue forecast — this directly reduces expected near‑term revenue and is the primary negative catalyst for today’s drop. Benzinga: Royalty rift report
Negative Sentiment: Additional insider sales (SVP Celia Eckert and VP John Desjarlais sold shares the same day) amplify investor concern about insider selling patterns and contributed to negative sentiment. Xencor also posted a formal update on its Ultomiris royalty forecast via its announcement. Yahoo Finance: Xencor royalty forecast change

Hedge Funds Weigh In On Xencor

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Hantz Financial Services Inc. increased its holdings in Xencor by 209.1% in the 3rd quarter. Hantz Financial Services Inc. now owns 3,187 shares of the biopharmaceutical company's stock valued at $37,000 after purchasing an additional 2,156 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of Xencor by 77.1% during the third quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company's stock worth $39,000 after purchasing an additional 1,449 shares in the last quarter. Farther Finance Advisors LLC purchased a new stake in shares of Xencor in the third quarter worth about $44,000. Tower Research Capital LLC TRC grew its stake in shares of Xencor by 118.4% in the second quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company's stock valued at $44,000 after buying an additional 3,018 shares in the last quarter. Finally, Federated Hermes Inc. grew its stake in shares of Xencor by 114.3% in the third quarter. Federated Hermes Inc. now owns 3,947 shares of the biopharmaceutical company's stock valued at $46,000 after buying an additional 2,105 shares in the last quarter.

About Xencor

(Get Free Report)

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor's research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.